Trial Profile
Effect of canagliflozin on the disposition index, a marker of pancreatic beta-cell function, in type 2 diabetic patients: a randomized controlled study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Aug 2020
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms CANDI-beta STUDY
- 10 Aug 2020 Status changed from active, no longer recruiting to completed.
- 03 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 03 Apr 2018 Status changed from not yet recruiting to recruiting.